3Sugitani A, Kitada H, Ota M, et al. Revival of effective and safe high-dose mizoribine for the kidney transplantation [ J]. Clin Transplant ,2006, 20(5) :590.
4Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[ J]. Clin Pharmacokinet, 2007,46( 1 ) : 13.
5Azzariti A, Porcelli L, Gatti G, et al. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells [ J ] . Biochem Pharmacol, 2008, 75 (5):1 035.
6Kaplan B, West P, Neeley H, et al. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL - 2 receptor blockade in an islet transplant recipient[J]. Clin Transplant ,2008,22(2) :250.
7Wissing KM, Fomegne G, Broeders N, et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti- interleukin-2 receptor antibodies [ J]. Transplantation, 2008,85 (3):411.
8Harper EG, Simpson EL, Takiguchi RH, et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4^+ T cells that express cutaneous lymphocyte antigen [ J ]. J Invest Dermatol , 2008, 128(5) :1 173.
9Budde K, Knoll G, Curtis J, et al. Long - term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to entericcoated mycophenolate sodium ( EC - MPA, myfortic ) [ J ]. Clin Nephrol,2006,66( 2 ) : 103.
10Plaumann S, Blume R, Borchers S, et al. Activation of the dual-leucine-zipper-bearing kinase and induction of beta-cell apoptosis by the immunosuppressive drug cyclosporin A [ J ]. Mol Pharmacol, 2008,73 (3) : 652.
